| Name | Title | Contact Details |
|---|---|---|
Anindita Sinha |
Vice President of Commercial | Profile |
Gianine Esposito |
Senior Vice President and Chief Human Resources Officer | Profile |
Martin Buckland |
Vice President, US New Products | Profile |
Emergency call systems from wireless nurse call systems to wireless emergency response pendants and door monitoring systems
Powered by its artificial intelligence software platform, nferX, nference`s mission is to synthesize the exponentially growing biomedical knowledge. nferX uses state-of-the-art neural networks (shallow and deep learning models) for real-time, automated extraction of knowledge from the commercial, scientific and regulatory body of literature.
ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Validation Professionals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.